Oncology

Your Article Summary

See Latest Articles

Human papillomavirus type 16 and 18 in primary lung cancers—a meta-analysis
Carcinogenesis, 10/12/09

Srinivasan M et al. – Lung cancer is the leading cause of cancer mortality worldwide. A possible carcinogenic role of human papillomavirus (HPV) has been investigated for >20 years and has major clinical and public health implications.

• Meta-analysis to assess prevalence of HPV16 and HPV18 in primary lung cancers (2435 subjects from 37 published studies)

• Overall HPV prevalence ranged from 0.0 to 78.3% with large heterogeneity across geographic regions and histological tissue types A
• Higher proportion, 50% (7/14), of European studies reported low or no HPV prevalence (0–10%) compared with the Asian studies, 22% (4/18)
• When analysis was limited to HPV16 and HPV18 prevalence, a higher prevalence in Asia (HPV16 = 11.6% and HPV18 = 8.8%) than in Europe (HPV16 = 3.5% and HPV18 = 3.6%) observed
• Studies using HPV-specific primers resulted in higher prevalence rates than consensus HPV primers (HPV16: Asia = 13% and Europe = 6%; HPV18: Asia = 13% and Europe = 5%)

Today in Lung/Thoracic Oncology...keeping you current

Receive free subspecialty "5-minute updates" via email

Comparative proteomic profiling identified sorcin being associated with gemcitabine resistance in non-small cell lung cancer
Medical Oncology, 12/17/09

Overexpression of Phospho-eIF4E Is Associated with Survival through AKT Pathway in Non–Small Cell Lung Cancer
Clinical Cancer Research, 12/17/09

Hepatocyte Growth Factor Reduces Susceptibility to an Irreversible Epidermal Growth Factor Receptor Inhibitor in EGFR-T790M Mutant Lung Cancer
Clinical Cancer Research, 12/17/09

 See all of Lung/Thoracic Oncology